Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Jennifer Yon-Li Wo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-9872-5912; OpenAlex author ID A5074136628, A5135286809. Sources: ClinicalTrials.gov.

Their work

Papers
52 (first author 8, last author 5)
Trials
5 (principal investigator on 5)
Grants
0
Labs led
1
Collaborators
187
Papers, trials and grants by year

2011: 1 trial · 2012: 2 papers, 1 trial · 2013: 4 papers, 1 trial · 2014: 3 papers · 2015: 1 paper · 2016: none · 2017: 1 paper · 2018: 6 papers, 1 trial · 2019: 3 papers, 1 trial · 2020: 4 papers · 2021: 5 papers · 2022: 7 papers · 2023: 4 papers · 2024: 4 papers · 2025: 4 papers · 2026: 4 papers

Papers 50 of 52

  1. Neoadjuvant Chemotherapy With or Without Radiotherapy in Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2026.3716↗
  2. Neoadjuvant stereotactic body vs conventionally fractionated radiation therapy for borderline resectable and locally advanced pancreatic cancer: a propensity s… Co-author DOI 10.1016/j.gassur.2026.102358↗
  3. Actual Five-year Survival After Neoadjuvant Therapy and Resection for Localized Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000007214↗
  4. Immune and stromal features of durable complete response to radiation and dual immune checkpoint blockade in pancreatic cancer Co-author DOI 10.64898/2026.08.06.26359422↗
  5. Best Practices for Delivering Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2024.5191↗
  6. NRG Oncology International Consensus Contouring Atlas on Target Volumes and Dosing Strategies for Dose-Escalated Pancreatic Cancer Radiation Therapy. Co-author DOI 10.1016/j.ijrobp.2024.10.026↗
  7. The Pdgfd-Pdgfrb axis orchestrates tumor-nerve crosstalk in pancreatic cancer Co-author DOI 10.1101/2025.08.26.672505↗
  8. Evaluating CBCT-Guided Adaptive Radiotherapy for Pancreatic Cancer Using Synthetic CBCT Data. Co-author DOI 10.3390/curroncol32020060↗
  9. Small steps can lead to substantial breakthroughs: moving the therapeutic needle forward in pancreatic cancer. Last author DOI 10.1016/s1470-2045(24)00290-0↗
  10. Spatially resolved analysis of pancreatic cancer identifies therapy-associated remodeling of the tumor microenvironment. Co-author DOI 10.1038/s41588-024-01890-9↗
  11. Feasibility, Safety, and Efficacy of Aggressive Multimodal Management of Elderly Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000006131↗
  12. Establishing a Role for Local Therapy in Oligometastatic Pancreatic Cancer. Last author DOI 10.1200/jco-24-01264↗
  13. Portal Vein or Superior Mesenteric Vein Thrombosis with Dose-Escalated Radiation for Borderline or Locally Advanced Pancreatic Cancer. Co-author DOI 10.1007/s11605-023-05796-5↗
  14. Underlying Bias in the Treatment of Pancreatic Cancer: Minorities Treated at the Same Facilities are Less Likely to Receive Neoadjuvant Therapy. Co-author DOI 10.1097/sla.0000000000005354↗
  15. Tolerability, Attrition Rates, and Survival Outcomes of Neoadjuvant FOLFIRINOX for Nonmetastatic Pancreatic Adenocarcinoma: Intent-to-Treat Analysis. Co-author DOI 10.1097/xcs.0000000000000499↗
  16. Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3+ Cancer Cells in Locally Advanced Pancreatic… Co-author DOI 10.1158/1078-0432.ccr-22-1630↗
  17. Arterial involvement and resectability scoring system to predict R0 resection in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemor… Co-author DOI 10.1007/s00330-021-08304-y↗
  18. Single-nucleus and spatial transcriptome profiling of pancreatic cancer identifies multicellular dynamics associated with neoadjuvant treatment. Co-author DOI 10.1038/s41588-022-01134-8↗
  19. A Combination of Biochemical and Pathological Parameters Improves Prediction of Postresection Survival After Preoperative Chemotherapy in Pancreatic Cancer: Th… Co-author DOI 10.1097/sla.0000000000004143↗
  20. Prospective Phase II Trials Validate the Effect of Neoadjuvant Chemotherapy on Pattern of Recurrence in Pancreatic Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000004585↗
  21. Supportive Oncology Care at Home Intervention for Patients With Pancreatic Cancer. Co-author DOI 10.1200/op.22.00088↗
  22. ASO Research Letter: Trends in Location of Death for Individuals with Pancreatic Cancer in the United States. Co-author DOI 10.1245/s10434-021-11058-y↗
  23. Treatment-associated remodeling of the pancreatic cancer endothelium at single-cell resolution. Co-author DOI 10.3389/fonc.2022.929950↗
  24. Conditional Survival in Resected Pancreatic Ductal Adenocarcinoma Patients Treated with Total Neoadjuvant Therapy. Co-author DOI 10.1007/s11605-020-04897-9↗
  25. Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial. Co-author DOI 10.1038/s43018-021-00269-7↗
  26. Tumor Microenvironment Immune Response in Pancreatic Ductal Adenocarcinoma Patients Treated With Neoadjuvant Therapy. Co-author DOI 10.1093/jnci/djaa073↗
  27. Liver Metastasis-Directed Ablative Radiotherapy in Pancreatic Cancer Offers Prolonged Time Off Systemic Therapy in Selected Patients: Data From a Multi-institu… Last author DOI 10.1097/mpa.0000000000001822↗
  28. Intraoperative Radiation Mitigates the Effect of Microscopically Positive Tumor Margins on Survival Among Pancreatic Adenocarcinoma Patients Treated with Neoad… Co-author DOI 10.1245/s10434-020-09444-z↗
  29. Clinical staging in pancreatic adenocarcinoma underestimates extent of disease. First author DOI 10.1016/j.pan.2020.03.011↗
  30. Single-nucleus and spatial transcriptomics of archival pancreatic cancer reveals multi-compartment reprogramming after neoadjuvant treatment Co-author DOI 10.1101/2020.08.25.267336↗
  31. Pancreatic ductal adenocarcinoma: tumour regression grading following neoadjuvant FOLFIRINOX and radiation. Co-author DOI 10.1111/his.14086↗
  32. Intraoperative Radiation Therapy (IORT) for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (BR/LA PDAC) in the Era of Modern Neoad… First author DOI 10.1245/s10434-019-08084-2↗
  33. Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical… First author DOI 10.1001/jamaoncol.2019.0892↗
  34. Elective nodal irradiation with simultaneous integrated boost stereotactic body radiotherapy for pancreatic cancer: Analyses of planning feasibility and geomet… Co-author DOI 10.1002/acm2.12528↗
  35. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX. Co-author DOI 10.1097/sla.0000000000002600↗
  36. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical … First author DOI 10.1001/jamaoncol.2018.0329↗
  37. Pilot study on the impact of F18-labeled thymidine PET/CT on gross tumor volume identification and definition for pancreatic cancer. Co-author DOI 10.1016/j.prro.2017.09.008↗
  38. Intraoperative Radiotherapy in the Era of Intensive Neoadjuvant Chemotherapy and Chemoradiotherapy for Pancreatic Adenocarcinoma. First author DOI 10.1097/coc.0000000000000336↗
  39. Tolerability and Long-term Outcomes of Dose-Painted Neoadjuvant Chemoradiation to Regions of Vessel Involvement in Borderline or Locally Advanced Pancreatic Ca… Co-author DOI 10.1097/coc.0000000000000349↗
  40. Are Staging Computed Tomography (CT) Scans of the Chest Necessary in Pancreatic Adenocarcinoma? Co-author DOI 10.1245/s10434-018-6764-3↗
  41. Association Between Very Small Tumor Size and Decreased Overall Survival in Node-Positive Pancreatic Cancer. Last author DOI 10.1245/s10434-018-6832-8↗
  42. Predictors of Early Mortality After Surgical Resection of Pancreatic Adenocarcinoma in the Era of Neoadjuvant Treatment. Co-author DOI 10.1097/mpa.0000000000000731↗
  43. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Co-author DOI 10.1097/sla.0000000000000867↗
  44. A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable … Co-author DOI 10.1016/j.ijrobp.2014.03.034↗
  45. Delaying chemoradiation until after completion of adjuvant chemotherapy for pancreatic cancer may not impact local control. Co-author DOI 10.1016/j.prro.2013.07.006↗
  46. Phase I study of neoadjuvant accelerated short course radiation therapy with photons and capecitabine for resectable pancreatic cancer. Co-author DOI 10.1016/j.radonc.2013.10.027↗
  47. Updated long-term outcomes and prognostic factors for patients with unresectable locally advanced pancreatic cancer treated with intraoperative radiotherapy at… Last author DOI 10.1002/cncr.28329↗
  48. Chemoradiation therapy: localized esophageal, gastric, and pancreatic cancer. First author DOI 10.1016/j.soc.2013.02.005↗
  49. FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. Co-author DOI 10.1634/theoncologist.2012-0435↗
  50. The controversial role of chemoradiation for patients with locally advanced pancreatic cancer. First author DOI 10.1634/theoncologist.2013-0270↗

Trials 5

  1. Electron Beam Intraoperative Radiation Therapy Following Chemoradiation in Patients With Pancreatic Cancer With Vascular Involvement Principal investigator NCT03716531↗
  2. Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer Principal investigator NCT03563248↗
  3. Radiation w/FOLFIRINOX-Losartan for Pancreatic Cancer Principal investigator NCT01821729↗
  4. FOLFIRINOX + RT for Pancreatic Cancer Principal investigator NCT01591733↗
  5. Short Course Radiation Therapy With Proton or Photon Beam Capecitabine and Hydroxychloroquine for Resectable Pancreatic Cancer Principal investigator NCT01494155↗

Closest collaborators

The 25 strongest of 187 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Theodore Sunki Hong · 46 shared papers, 2012–2026 · strength 5.05
  2. Keith D. Lillemoe · 27 shared papers, 2013–2026 · strength 2.93
  3. David P. Ryan · 29 shared papers, 2012–2026 · strength 2.82
  4. Colin D. Weekes · 17 shared papers, 2019–2026 · strength 2.70
  5. Motaz Qadan · 19 shared papers, 2019–2026 · strength 2.64
  6. Cristina Rosa Ferrone · 25 shared papers, 2013–2024 · strength 2.25
  7. Carlos F. Fernandez-del Castillo · 22 shared papers, 2012–2024 · strength 1.92
  8. Lawrence Scott Blaszkowsky · 21 shared papers, 2012–2026 · strength 1.91
  9. Hannah Johnson Roberts · 7 shared papers, 2024–2026 · strength 1.48
  10. Carlos Fernández-del Castillo · 11 shared papers, 2013–2026 · strength 1.36
  11. Aparna R. Parikh · 11 shared papers, 2018–2026 · strength 1.34
  12. David Tsai Ting · 12 shared papers, 2015–2026 · strength 1.28
  13. Priyadarshini Pathak · 3 shared papers, 2024–2026 · strength 0.73
  14. Vikram Deshpande · 8 shared papers, 2014–2022 · strength 0.69
  15. Andrew Louis Warshaw · 8 shared papers, 2013–2023 · strength 0.69
  16. Mari A. Mino-Kenudson · 5 shared papers, 2020–2025 · strength 0.63
  17. Zhi Ven Fong · 4 shared papers, 2018–2024 · strength 0.57
  18. Ryan David Nipp · 7 shared papers, 2017–2022 · strength 0.55
  19. Eunice Lee Kwak · 12 shared papers, 2012–2019 · strength 0.55
  20. William L. Hwang · 4 shared papers, 2020–2025 · strength 0.55
  21. Jimmy A. Guo · 4 shared papers, 2020–2025 · strength 0.55
  22. Jon Michael Harrison · 4 shared papers, 2020–2026 · strength 0.54
  23. Theodoros P. Michelakos · 5 shared papers, 2019–2022 · strength 0.53
  24. Carina Shiau · 3 shared papers, 2022–2025 · strength 0.48
  25. Janet E. Murphy · 7 shared papers, 2013–2022 · strength 0.46

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.